236 related articles for article (PubMed ID: 20700120)
1. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
Lammers LA; Mathijssen RH; van Gelder T; Bijl MJ; de Graan AJ; Seynaeve C; van Fessem MA; Berns EM; Vulto AG; van Schaik RH
Br J Cancer; 2010 Sep; 103(6):765-71. PubMed ID: 20700120
[TBL] [Abstract][Full Text] [Related]
2. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
3. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
4. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
Seruga B; Amir E
Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
[TBL] [Abstract][Full Text] [Related]
8. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM; Carey LA; McLeod HL
Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.
Mayer SE; Weiss NS; Chubak J; Doody DR; Carlson CS; Makar KW; Wurscher MA; Malone KE
Cancer Causes Control; 2019 Jan; 30(1):103-112. PubMed ID: 30542984
[TBL] [Abstract][Full Text] [Related]
11. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
13. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
Ahern TP; Pedersen L; Cronin-Fenton DP; Sørensen HT; Lash TL
Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2562-4. PubMed ID: 19690182
[TBL] [Abstract][Full Text] [Related]
14. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.
Sestak I; Kealy R; Nikoloff M; Fontecha M; Forbes JF; Howell A; Cuzick J
Br J Cancer; 2012 Jul; 107(2):230-3. PubMed ID: 22735900
[TBL] [Abstract][Full Text] [Related]
15. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.
Cronin-Fenton DP; Lash TL
Expert Rev Clin Pharmacol; 2011 May; 4(3):363-77. PubMed ID: 21709817
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
Stearns V; Rae JM
Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
20. Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.
Blancas I; Linares-Rodríguez M; Martínez de Dueñas E; Herrero-Vicent C; Molero-Mir MD; Garrido JM; Rodríguez-Serrano F
Breast; 2023 Jun; 69():342-348. PubMed ID: 37011481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
